Template:SUIT-016: Difference between revisions

From Bioblast
No edit summary
No edit summary
ย 
(8 intermediate revisions by 5 users not shown)
Line 1: Line 1:
[[Image:SUIT-MitoFit.png|right|190px|link=http://www.bioblast.at/index.php/MitoPedia:_SUIT |MitoPedia: SUIT]]
[[Image:SUIT-MitoFit.png|right|190px|link=http://www.bioblast.at/index.php/MitoPedia:_SUIT |MitoPedia: SUIT]]
== Steps and respiratory states ==
== Steps and respiratory states ==
[[File:1OctM;2D;3G;3c;4S;5Rot;6Omy;7U;8Ama.png|400px]]
[[File:1OctM;2D;3G;4S;5Rot;6Omy;7U;8Ama.png|400px]]




Line 9: Line 9:
|-
|-
| 1OctM
| 1OctM
| [[OctM]]<sub>''[[L]]''</sub>
| [[OctM]]<sub>''[[LEAK respiration|L]]''(n)</sub>
| [[Fatty acid oxidation pathway control state| F(N)]]
| [[Fatty acid oxidation pathway control state| F(N)]]
| CETF
| CETF
Line 38: Line 38:
*{{Template:SUIT F}} & {{Template:SUIT N}}
*{{Template:SUIT F}} & {{Template:SUIT N}}
*{{Template:SUIT FN}}
*{{Template:SUIT FN}}
*{{Template:SUIT OXPHOS}}
|-
| 3c
| [[OctGM]]<sub>''[[OXPHOS|P]]''</sub>
| [[FN]]
| CETF&I
| 1OctM;2D;3G;3c
*{{Template:SUIT F}} & {{Template:SUIT N}}
*{{Template:SUIT FN}}
* {{Template:SUIT c}}
*{{Template:SUIT OXPHOS}} ย 
*{{Template:SUIT OXPHOS}} ย 


Line 57: Line 45:
| [[FNS]]
| [[FNS]]
| CETF&CI&II
| CETF&CI&II
| 1OctM;2D;3G;3c;4S
| 1OctM;2D;3G;4S


*{{Template:SUIT F}} & {{Template:SUIT N}} & {{Template:SUIT S}}
*{{Template:SUIT F}} & {{Template:SUIT N}} & {{Template:SUIT S}}
Line 68: Line 56:
| [[S]]
| [[S]]
| CII
| CII
| 1OctM;2D;3G;3c;4S;5Rot
| 1OctM;2D;3G;4S;5Rot


*{{Template:SUIT Rot}}
*{{Template:SUIT Rot}}
Line 76: Line 64:
|-
|-
| 6Omy
| 6Omy
| [[S]]<sub>''[[L]]''</sub>
| [[S]]<sub>''[[LEAK respiration|L]]''(Omy)</sub>
| [[S]]
| [[S]]
| CII
| CII
| 1OctM;2D;3G;3c;4S;5Rot;6Omy
| 1OctM;2D;3G;4S;5Rot;6Omy


*{{Template:SUIT S}}
*{{Template:SUIT S}}
*{{Template:SUIT L(n)}}
*{{Template:SUIT L(Omy)}}


|-
|-
Line 89: Line 77:
| [[S]]
| [[S]]
| CII
| CII
| 1OctM;2D;3G;3c;4S;5Rot;6Omy;7U
| 1OctM;2D;3G;4S;5Rot;6Omy;7U


*{{Template:SUIT S}}
*{{Template:SUIT S}}
Line 100: Line 88:
| ย 
| ย 
| ย 
| ย 
| 1OctM;2D;3G;3c;4S;5Rot;6Omy;7U;8Ama
| 1OctM;2D;3G;4S;5Rot;6Omy;7U;8Ama


*{{Template:SUIT Ama}}
*{{Template:SUIT Ama}}


|}
|}
{{Template:Keywords in SUIT protocols}}
{{Template:SUIT CIV}}
{{Keywords: SUIT protocols}}

Latest revision as of 13:08, 25 November 2020

MitoPedia: SUIT

Steps and respiratory states

1OctM;2D;3G;4S;5Rot;6Omy;7U;8Ama.png


Step State Pathway Q-junction Comment - Events (E) and Marks (M)
1OctM OctML(n) F(N) CETF 1OctM
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
  • Low concentration of malate, typically 0.1 mM, does not saturate the N-pathway; but saturates the F-pathway.
  • Non-phosphorylating resting state (LEAK state); LEAK respiration L(n) in the absence of ADP, ATP, AMP (no adenylates).
2D OctMP F(N) CETF 1OctM;2D
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
  • Low concentration of malate, typically 0.1 mM, does not saturate the N-pathway; but saturates the F-pathway.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
3G OctGMP FN CETF&I 1OctM;2D;3G
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration. & NADH-linked substrates (type N-pathway to Q).
  • Respiratory stimulation by simultaneous action of the F-pathway and N-pathway with convergent electron flow in the FN-pathway for evaluation of an additive or inhibitory effect of F.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
4S OctGMSP FNS CETF&CI&II 1OctM;2D;3G;4S
5Rot SP S CII 1OctM;2D;3G;4S;5Rot
6Omy SL(Omy) S CII 1OctM;2D;3G;4S;5Rot;6Omy
  • Succinate, S ( type S-pathway to Q).
  • Non-phosphorylating resting state (LEAK state); LEAK-respiration, L(Omy), after blocking the ATP synthase with oligomycin.
7U SE S CII 1OctM;2D;3G;4S;5Rot;6Omy;7U
8Ama ROX 1OctM;2D;3G;4S;5Rot;6Omy;7U;8Ama
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated after addition of antimycin A (inhibitor of CIII). Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration (mt).
Step Respiratory state Pathway control ET-Complex Comment
## AsTm AsTmE CIV CIV
## Azd CHB


Questions.jpg


Click to expand or collaps
Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>
Cookies help us deliver our services. By using our services, you agree to our use of cookies.